who may not have been successful with treatment or other addiction therapies such as oral opioid agonist therapy (OAT) and other appropriate empirically supported services. The project will identify ...
Aside from Jazz Pharmaceuticals’ Epidyolex, which has published Phase II outcomes in a study evaluating its efficacy as an adjunct treatment to patients on opioid agonist therapy (NCT04567784 ...
Injectable opioid agonist therapy, extended-release agonists, and antagonists are beyond the scope of this guideline. “The management of opioid use disorder is a rapidly changing and ever ...
Injectable opioid agonist therapy, extended-release agonists, and antagonists are beyond the scope of this guideline. The management of opioid use disorder is a rapidly changing and ever-evolving ...